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Background: Gamma-synuclein (SNCG) has previously been demonstrated to be significantly correlated with
metastatic malignancies; however, in-depth investigation of SNCG in prostate cancer is still lacking. In the present
study, we evaluated the role of SNCG in prostate cancer progression and explored the underlying mechanisms.
Methods: First, alteration of SNCG expression in LNCaP cell line to test the ability of SNCG on cellular properties
in vitro and vivo whenever exposing with androgen or not. Subsequently, the Dual-luciferase reporter assays were
performed to evaluate whether the role of SNCG in LNCaP is through AR signaling. Last, the association between
SNCG and prostate cancer progression was assessed immunohistochemically using a series of human prostate tissues.
Results: Silencing SNCG by siRNA in LNCaP cells contributes to the inhibition of cellular proliferation, the induction of
cell-cycle arrest at the G1 phase, the suppression of cellular migration and invasion in vitro, as well as the decrease of
tumor growth in vivo with the notable exception of castrated mice. Subsequently, mechanistic studies indicated that
SNCG is a novel androgen receptor (AR) coactivator. It interacts with AR and promotes prostate cancer cellular growth
and proliferation by activating AR transcription in an androgen-dependent manner. Finally, immunohistochemical
analysis revealed that SNCG was almost undetectable in benign or androgen-independent tissues prostate lesions. The
high expression of SNCG is correlated with peripheral and lymph node invasion.
Conclusions: Our data suggest that SNCG may serve as a biomarker for predicting human prostate cancer progression
and metastasis. It also may become as a novel target for biomedical therapy in advanced prostate cancer.
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Prostate cancer (PCa) is the most commonly diagnosed
malignancy and the second highest cause of cancer
death in American men. Thus, PCa poses a major public
health problem in the United States and worldwide [1].
In recent years, an upward trend in prostate cancer inci-
dence has also been observed in Asian countries [2], pos-
sibly because of an increase in an aged population [3].
Although prostate-specific antigen (PSA)-based screen-
ing has become very common in the clinic, this marker* Correspondence: sunyh@medmail.com.cn
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reproduction in any medium, provided the orlacks specificity [4]. Up to 25% of men with the disease
have PSA levels less than 4.0 ng/ml, and “abnormal” or
elevated PSA levels can also result from benign pros-
tatic conditions [5]. A substantial proportion of screen-
detected prostate cancers may have been overdiagnosed
and subsequently overtreated, while others may not
have been detected and treated early enough. The pre-
dictive value of conventional clinicopathological para-
meters for powerful prognosticators, such as pathological
tumor stage and lymph node metastatic disease, remains
limited. Widespread overtreatment has greatly increased
the social burden and poor quality of life. Therefore, it is
urgent to seek and refine prognostic information, which
is gained from pretreatment variables and prostate can-
cer biopsy specimens in particular.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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group of neuronal proteins that have been implicated in
neurodegenerative diseases and cancer [6,7]. The synu-
clein family consists of α-, β-, and γ-synuclein (SNCG).
The α- and β-synuclein proteins participate in the devel-
opment and function of the central nervous system, and
may be important in the etiology and pathogenesis of
neurodegenerative disorders such as Alzheimer’s and
Parkinson’s diseases [8-10]. SNCG is not clearly involved
in neurodegenerative diseases. However, a stage-specific
upregulation of SNCG has been found in advanced
breast carcinomas [11] and other malignancies, includ-
ing ovarian [12], gastric [13], esophagus [14], liver [15],
colon [16], pancreatic [17], and bladder cancers [18]. In
a pancreatic mouse model, SNCG emerged as the only
upregulated molecule in a high perineural invasion
group through proteomic and transcriptomic analysis
[17]. Overexpression of SNCG interferes with drug-
induced apoptotic responses [19] and mediates drug re-
sistance [20]. Moreover, studies to date indicate that
overexpression of SNCG compromises normal mitotic
checkpoint controls, resulting in multi-nucleation and
faster cell proliferation [21]. SNCG has been shown to
promote cancer invasion and metastasis in vitro and in
animal models [22]. There is a strong association be-
tween SNCG protein expression in primary tumors and
distant metastases in multiple cancers. It has been impli-
cated as a molecular indicator of metastasis in a wide
range of human cancers [23]. Currently, there is no good
biomarker for predicting the individual probability of
metastatic progression of prostate cancer after radical
prostatectomy. In this study, we explored if SNCG could
serve as a biomarker for predicting human prostate can-
cer progression and metastasis.
Methods
Cell lines
The androgen-dependent human advanced prostate cancer
cell line LNCaP was provided by Prof. Klaus Jung (Depart-
ment of Urology, University Hospital Charité, Humboldt
University, Germany). Androgen-independent PC-3 and
DU145 cell lines were obtained from the Institution of Bio-
chemistry and Cell Biology, the Chinese Academy of
Sciences (Shanghai, China). The androgen-independent
LNCaP (LNCaP-AI) cell subline was obtained from LNCaP
cells cultured in androgen-deprivation medium as previ-
ously described [24].
RNA interference
Small interfering oligonucleotides (oligo-166, 290 and
492) specifically targeting at human SNCG were
synthesized and annealed by Genepharma Co, Ltd
(Shanghai, China). The siRNA sequences were as follows:





(reverse) for oligo-492. Negative control siRNA sequences
were: 50-UUCUCCGAACGUGUCACGUTT-30 (forward)
and 50-ACGUGACACGUUCGGAGAATT-30 (reverse).
Establishment of stable SNCG cDNA-overexpressing and
siRNA-expressing LNCaP cell lines
Full-length cDNA of SNCG gene (AF017256) was ampli-
fied from a plasmid, pGST-SNCG (a gift sent by Dr. Jia
Zongchao in the Department of Biochemistry at the
Queen’s University, Canada), and subcloned into a lenti-
viral vector pLV-RFP (Shanghai Invabio Bio-technology
Co., China.) for construction of a lentiviral SNCG cDNA-
overexpressing vector pLV-RFP-SNCG. siSNCG (oligo-
166) or NC-negative was also constructed into a
pLV-RFP vector. RFP-SNCG or RFP-siSNCG (oligo-166)
vector was transfected into LNCaP cells. RFP empty
vector or RFP-NC-negative control were induced in the
same cells as the controls. After selection by puromycin
treatment, an RFP positive clone was selected for
utilization in the subsequent experiments. Transient
transfection was used for cell culture experiments, and
stably-transfected cells for some cell culture experiments
and animal experiments. All of the experiments were
performed three times and the results were reproducible.
Quantitative RT-PCR
Total RNA was extracted with Trizol reagent (Invitrogen).
Two micrograms of total RNA was used for the RT reac-
tion (20 μl total volume) using the First-Strand cDNA
synthesis kit (#K1621, Fermentas). One microliter of the
cDNA was used as the template for quantitative PCR
(SYBR Green #K0221, Fermentas), which was performed
using the Lightcycler Detection System (Roche, Basel,
Switzerland), according to the manufacturer’s instruc-
tions. The expression level of human glyceraldehyde
3-phosphate dehydrogenase (GAPDH) gene was used
for normalization of SNCG mRNA expression level.
The primers used in this study were 50-CAAGAA
GGGCTTCTCCATCGCCAAGG-30 (forward) and 50-C
CTCTTTCTCTTTGGATGCCACACCC-30 (reverse) for
the human SNCG gene; 50-TCTCAAGAGTTTGGAT
GGCTCC-30 (forward) and 50-TCACTGGGTGTGGA
AATAGATG-30 (reverse) for the human androgen re-
ceptor (AR) gene; 50-TGGGAGTGCGAGAAGCATTC-30
(forward) and 50-GCACACAGCATGAACTTGGTCAC-30
(reverse) for the human prostate specific antigen (PSA)
gene; 50-CGGAGTCAACGGATTTGGTCGTATTGG-30
(forward) and 50-GCTCCTGGAAGATGGTGATGGG
ATTTCC-30 (reverse) for the GAPDH gene. Values
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ent experiments, each performed in triplicate.
Co-immunoprecipitation and western blot analyses
A co-immunoprecipitation assay was performed as pre-
viously described [25]. SNCG polyclonal antibodies
(1:1000, sc-10699, Santa Cruz) and AR antibody (sc-815,
Santa Cruz) were used for western blot and co-
immunoprecipitation assay.
Cell migration assay
Cell migration was measured using a Transwell chamber
(Millipore, Germany). Briefly, RPMI 1640 medium con-
taining 10% fetal bovine serum (FBS) was added into
the lower compartment as a chemoattractant. After
24 h transfection, the cells were suspended in RPMI 1640
medium containing 1% FBS were seeded in the upper
chamber and incubated for 20 hours at 37°C. The two
chambers were separated by polycarbonate filters (8 μm
pore size). At the end of incubation, cells on the top side
of the filter were wiped off, and cells that migrated to the
lower surface of the filter were fixed and stained with
0.1% crystal violet. Cell numbers were counted in five
separate fields using light microscopy. The data were
expressed as the mean value of cells in five fields based
on three independent experiments.
Cell invasion assays
Invasion assays were performed using 24-well Transwell
units with 8 μm pore size polycarbonate inserts. The
polycarbonate membranes were coated with Matrigel
(Becton Dickinson) and cultured at 37°C for 1 h. After
24 h transfection, the cells (1.0 × 105) were suspended in
200 μl of RPMI1640 medium containing 5% FBS and
seeded in the upper compartment of the Transwell unit.
Next, 500 μl of RPMI 1640 medium containing 10% FBS
was added into the lower compartment as a chemo-
attractant. After 48 h incubation, cells on the upper
side of the membrane were then removed, whereas the
cells that migrated through the membrane to the under-
side were fixed and stained with 0.1% crystal violet.
Cell numbers were counted in five separate fields
using light microscopy. The data were expressed as
the mean value of cells in five fields based on three
independent experiments.
Cell proliferation assays
Proliferation of LNCaP cells was evaluated by WST-8
Cell Counting Kit-8 (Beyotime, Jiangsu, China) assay
according to the manufacturer’s instructions. This assay
is based on the cleavage of the tetrazolium salt WST-8
by mitochondrial dehydrogenase in viable cells. Cells/
well (1 × 103) were incubated with 100 μl culture
medium in 96-multiwell plates. Cells were cultured for1, 2, 3, 5, and 7 days before addition of 10 μl CCK-8 to
the culture medium in each well. After a further 4 h in-
cubation period at 37°C, absorbance at 450 nm of each
well was measured with a microplate reader (BioTek
Instruments, Inc., USA). Each experiment was repeated
three times, and the data represent the mean of all
measurements.
Cell cycle analysis
Cell cycle distribution was analyzed by flow cytometry.
After the indicated treatments, cells were trypsinized,
rinsed with PBS, and fixed with 70% ethanol at 4°C over-
night. Fixed cells were washed with PBS and suspended
in 500 μl of propidium iodide/Triton X-100/RNase
staining solution for 30 minutes at 37°C in the dark.
Cell cycle analysis was performed using a flow cyt-
ometer (MACSQuant™ Analyzer, Miltenyi Biotec).
DNA histograms were analyzed by the MACSQuantify™
version 2.1.
Dual luciferase reporter assays
Cells were transfected with 800 ng of a reporter plasmid
pMMTV-LUC containing four different AREs. Then,
3 ng of a pRL-TK plasmid was also co-transfected as the
internal control. After 24 h, the cells were treated with
either ethanol or 1.0 nM DHT for 24 h. Luciferase assays
were performed using the Promega Dual Luciferase
Reporter Assay system.
Tumorigenesis of human prostate cancer cells in nude
male mice
Male athymic nude mice at 6–8-weeks-old were pur-
chased from the Shanghai Cancer Institute, China.
Animal handling and experimental procedures were
approved by the Animal Investigation Committee of the
Shanghai Cancer Institute. Tumors were generated by
subcutaneous injection of 5 × 106 siSNCG-166 and NC
stably-transfected cells/mouse (n = 8 per group) mixed
with 0.1 ml of Matrigel (BD Biosciences). The mice of
the other two groups were castrated and then injected
with stable SNCG cDNA-expressing LNCaP cells or RFP
empty vector-expressing LNCaP cells as a control, and
the tumors were measured twice weekly with a caliper.
Tumor volume (cm3) was calculated by the formula
ab2/2, where “a” was the largest diameter and “b”
was the smallest diameter of the tumor.
Tissue specimens and prostate tissue microarray (TMA)
Protocols involving human materials were approved by
the institutional ethics committee of Shanghai Changhai
Hospital, Shanghai, China. Formalin-fixed paraffin-
embedded tissue specimens were obtained from the
archives of the Department of Pathology. The specimens
consisted of prostatitis tissues (n = 10), benign prostatic
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tate cancer (n = 122), and androgen-independent prostate
cancer tissues (n = 5). Androgen-independent prostate
cancer was defined as patients who become refractory
after one to three years and resume growth despite hor-
mone therapy. Tumors were staged following the stand-
ard Tumor-Node-Metastasis (TNM) methodology of
American Joint Committee on Carcinoma (AJCC)/Union
for International Cancer Control (UICC). This cohort of
androgen-dependent prostate cancer patients did not
receive neoadjuvant therapy such as radiation or hor-
monal therapy.
A prostate tissue microarray (TMA) was made from
the formalin-fixed paraffin-embedded tissue specimens.
Briefly, one core tissue-biopsy (diameter 0.6 mm) was
taken from the marked region of individual paraffin-
embedded prostate tumors and precisely arrayed into a
new recipient paraffin block with a custom built preci-
sion instrument. Three TMAs containing an identical
set of tumors were constructed. After the block con-
struction was completed, 8- to 10-μm sections were cut
with a microtome. The presence of tumor tissue on the
arrayed samples was verified by H&E staining.
Antibodies and immunohistochemical analysis
Goat anti-SNCG polyclonal antibody (sc-10699, Santa
Cruz Biotechnology, CA) or rabbit anti-AR polyclonal
antibody (sc-815, Santa Cruz Biotechnology, CA) were
used for immunochemical staining by a standard ABC
method. A semi-quantitative scoring system based on
the average number of SNCG-positive cells from five
randomly chosen × 400 fields was used to grade the ex-
pression levels. The mean value (n) was used to grade
the expression levels: +, 0 < n ≤ 30; ++, 30 < n ≤ 50; +++,
n > 50. Samples were independently evaluated under a
light microscope by two pathologists without prior
knowledge of the patients’ clinical data.
Statistical analysis
All data were analyzed with SAS9.1.3 (SAS Institute, Cary,
NC, USA). The Mann–Whitney Test was used to identify
differences between SNCG protein expression and clinico-
pathologic features of prostate cancer. The Pearson’s cor-
relation efficient analysis was applied across SNCG
expression with AR status. The independent-samples t-test
was analyzed for cell and animal experiments (mean ± SD).
P < 0.05 was considered statistically significant.
Results
Silencing of SNCG by small-interfering oligonucleotides in
LNCaP cells inhibits cellular proliferation and induces cell
cycle arrest at G1 phase
To investigate SNCG expression patterns in prostate
cancer, we first examined SNCG mRNA and proteinexpression levels in advanced human prostate cancer
cell lines, including androgen-dependent LNCaP and
androgen-independent DU145, PC3 and LNCaP-AI
(androgen-independent LNCaP). LNCaP-AI cell subline
was obtained from LNCaP cells cultured in androgen-
deprivation medium. AR protein in LNCaP-AI is higher
than in LNCaP, and LNCaP-AI cells showed stronger
proliferative ability than LNCaP cells in androgen-
deprivation culture medium. PSA secretion was stimu-
lated with increasing concentrations of DHT in both
LNCaP and LNCaP-AI cells, but the PSA secretion was
much higher for LNCaP cells than for LNCaP-AI cells.
RT-PCR was used to detect SNCG mRNA expression
levels in total RNA samples extracted from four cell lines.
The results showed that LNCaP cells expressed a high
level of SNCG mRNA compared to DU145, PC3 and
LNCaP-AI cells. Western blot analysis also revealed high
levels of SNCG protein expression in LNCaP cells; how-
ever, low or undetectable levels of SNCG protein expres-
sion were found in DU145, PC3 and LNCaP-AI cells
(Figure 1A).
To explore the effects of SNCG on prostate cancer
cellular growth and proliferation, we employed RNA
interference (RNAi) or full-length cDNA overexpression
of SNCG gene in LNCaP cells. Three different SNCG-
siRNAs and a negative control siRNA were transiently
transfected into LNCaP cells to identify which siRNA
sequence most potently suppressed SNCG mRNA
levels. SNCG-siRNA significantly inhibited the relative
expression of SNCG mRNA (oligo-166, 93% decrease;
oligo-290, 84% decrease; and oligo-492, 42% decrease),
whereas there was little difference between negative
control siRNA and parental cells (Figure 1B). Oligo-
166 was identified as the most potent suppressor of
SNCG expression in LNCaP cells. Full-length SNCG
cDNA sequence was sub-cloned into a pLeno-RFP
retroviral vector. SNCG-RFP vector or effective RNA
interference (siRNA) oligos was transiently transfected
to LNCaP cells, and empty vector or nonsense RNA
(NC) was transfected as the controls. A WST-8 Cell
Counting Kit-8 (Beyotime, Jiangsu, China) assay was used
for evaluation of cellular proliferation. RFP-labeled,
SNCG-overexpressing LNCaP cells showed an increase
in cellular proliferation compared to the control cells. As
expected, silencing of SNCG in LNCaP cells (siSNCG-
166) showed a decrease in cellular proliferation com-
pared to the control cells (Figure 1C). To analyze the
reasons for reduced cellular growth and proliferation in
SNCG siRNA-expressing LNCaP cells, flow cytometry
was used to examine cell cycle distribution. We observed
64.2% of siSNCG-166 cells were distributed in G1 phase,
whereas only 53.4% of negative control cells remained in
G1 phase (Figure 1D). Our results indicate that silencing
of SNCG by siRNA in LNCaP cells suppresses cellular
Figure 1 Suppression of SNCG in LNCaP Cells inhibits cellular proliferation and induces cell cycle arrest at G1. (A) Top: RT-PCR analysis
was used to evaluate SNCG mRNA expression levels in androgen-dependent (LNCaP) and androgen-independent human advanced prostate
cancer lines (DU145, PC3 and LNCaP-AI). Bottom: Western blot analysis revealed SNCG protein expression levels in the relevant cell lines. (B) Top:
RT-PCR analysis was used to evaluate SNCG mRNA expression in LNCaP cells after transient transfection with various siRNA constructs. Bottom:
Western blot analysis showed oligo-166 inhibited SNCG expression in LNCaP cells. (C) CCK-8 assay were performed for evaluation of the LNCaP
cellular proliferation. (D) Flow cytometry assay demonstrated that inhibition SNCG expression in LNCaP cell induced cell cycle arrest at G1. These
results are representative of three independent experiments. *P < 0.05, **P < 0.01.
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G1 phase.
Knockdown of SNCG by siRNA in LNCaP cells inhibits
cellular migration and invasion in vitro
To investigate the relationship between SNCG expres-
sion and prostate cancer cellular biological behavior, we
evaluated the effects of SNCG siRNA on cellular migra-
tion and invasion of LNCaP in vitro by chemotaxis and
Matrigel invasion assays using Transwell chambers
(Millipore, Germany). siSNCG-166 or nonsense RNA
(NC) was transiently transfected into LNCaP cells
(Figure 2). Chemotaxis or invasion through the Matrigel
by siSNCG-166-expressing LNCaP cells was reduced by
20% or 43%, respectively, compared to the NC group.
SNCG siRNA-expressing LNCaP cells showed a signifi-
cant reduction in prostate cancer cellular migration and
invasion compared to the control cells. The results sug-
gest that silencing of SNCG expression by siRNA inLNCaP cells contributes to the suppression of cellular
migration and invasion in vitro.
SNCG protein interacts with androgen receptor in human
prostate cancer cells
Since SNCG is expressed at high levels in androgen-
dependent and at low levels in androgen-independent
prostate cancer cells, we raised the question whether
SNCG is involved in mediating hormone-dependent
tumorigenicity. To test this, we investigated SNCG
mRNA expression in LNCaP cells with or without an-
drogen supplementation. After androgen deprivation,
SNCG expression levels in LNCaP cells decreased with
time (Figure 3A). To test whether the effects of dihydro-
testosterone (DHT) administration on SNCG expression
in LNCaP cells are mediated by androgen receptor (AR)
signaling, we examined the effects of anti-androgen (flu-
tamide, an AR antagonist) treatment on SNCG expres-
sion. Administration with anti-androgens mostly blocked
Figure 2 Knockdown of SNCG by siRNA in LNCaP cells suppresses cellular migration and invasion in vitro. (A) Inhibition of endogenous
SNCG expression by siRNA reduced the number of cellular migration to the lower Transwell chamber normalized by the negative control.
(B) SNCG knockdown decreased the number of cellular invasion by a Matrigel-Transwell assay compared to the negative control. Results are
representative of three independent experiments. **P < 0.01.
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modulates SNCG expression through AR signaling
(Figure 3B).
To examine whether AR protein physiologically inter-
acts with SNCG protein in human prostate cancer cells,
we performed a co-immunoprecipitation assay. The
lysates of LNCaP cells were immunoprecipitated with
either an anti-AR or an anti-SNCG antibody. Then the
membranes were immunoblotted with an anti-SNCG or
an anti-AR antibody, respectively. We detected an inter-
action between AR and SNCG proteins in the lysates of
SNCG-expressing LNCaP cells treated with or without
DHT (Figure 3C), which was strengthened following
DHT treatment. Under the same conditions, AR and
SNCG proteins did not co-immunoprecipitate when the
control IgG was used.
To further evaluate the relationship between SNCG
and AR-mediated PSA expression, we examined whether
altered SNCG expression in LNCaP cells results in
changes in PSA transcription in response to DHT treat-
ment. Knockdown of SNCG in LNCaP cells significantly
reduced PSA mRNA expression induced by DHT, com-
pared to the nonsense RNA control group (Figure 3D).
We also examined AR expression levels in SNCGsiRNA-expressing LNCaP cells. However, SNCG siRNA-
expressing LNCaP cells had no significant effect on AR
mRNA expression (Figure 3E). Then we examined the
effects of SNCG on AR transcriptional activity by luci-
ferase reporter assays. A plasmid containing androgen-
responsive elements (AREs) was transfected into
siSNCG-LNCaP cells or LNCaP cells transfected with
nonsense RNA as the control. AR luciferase activity
was significantly decreased with DHT treatment in
SNCG siRNA group in contrast to the nonsense RNA
group. These results suggest that SNCG is involved in
androgen-induced AR transcriptional activity (Figure 3F).
These data indicated that SNCG, as a coregulator of
AR, interact with AR protein and significantly affect AR
target gene PSA expression by enhancing androgen-
induced AR transcriptional activity.
SNCG is involved in restoration of androgen sensitivity in
LNCaP-AI cells
Because of the observation that SNCG expression was
regulated by androgen and was expressed a relatively low
level in LNCaP-AI cells, we asked whether SNCG overex-
pression in LNCaP-AI cells contributes to androgen re-
sponsiveness. We first established a stable, RFP-labeled
Figure 3 Interaction between SNCG and AR protein regulates androgen-induced transcriptional activity of AR. (A) After culture in
androgen-deprived medium, SNCG mRNA expression in LNCaP cells was detected by RT-PCR. (B) LNCaP cells were treated with increasing
amounts of androgens (dihydrotestosterone DHT at 0.1, 1.0, 10.0 and 100 nM) and anti-androgens (flutamide Flu at 0.1, 1.0, 10.0 and 100 μM) for
48 h before SNCG mRNA expression was analyzed by quantitative RT-PCR and compared to the levels in the parental LNCaP cells. (C) The co-IP
assay indicated that the interaction between SNCG and AR was strengthened by DHT. IgG-precipitated complexes were used as the control.
(D) PSA mRNA expression in siSNCG-LNCaP cells was measured after administration with androgen. (E) RT-PCR was used to detect the AR mRNA
expression in siSNCG-LNCaP cells with or without DHT administration. (F) Dual-luciferase reporter assays were performed to show the AR
transcriptional activity in siSNCG-LNCaP cells with or without DHT administration. *P < 0.05, **P < 0.01.
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line (Figure 4A), which was confirmed by fluorescence mi-
croscopy, RT-PCR and western blot. SNCG-overexpressing
LNCaP-AI cells treated with DHT showed a significant in-
crease in PSA mRNA expression compared to the control
LNCaP-AI cells. The elevated PSA levels were blocked by
flutamide treatment (Figure 4B). However, AR expression
levels in LNCaP-AI cells were not affected by SNCG over-
expression (Figure 4C). We found AREs activity detected
by luciferase reporter assay in SNCG-overexpressing cells
was significantly increased with DHT treatment compared
to RFP vector-transfected control cells (Figure 4D). Add-
itional DHT treatment did not significantly affect the
proliferation rate of LNCaP-AI cells. However, SNCG-
overexpressed LNCaP-AI cells showed an increase in cellu-
lar growth and proliferation in response to DHT treatment
(Figure 4E), indicating that SNCG protein functions in
affecting cellular growth response to DHT administration.
Our data suggest that SNCG overexpression restores an-
drogen sensitivity in LNCaP-AI cells via mediating AR
transcription activity.SNCG promotes tumorigenesis of androgen-dependent
prostate cancer cells in vivo
To investigate the effects of SNCG on LNCaP tumor
growth in vivo associated with androgen status, we first
analyzed tumorigenesis in response to androgen treat-
ment in nude male mice. Tumors were monitored by
caliper measurements (Figure 5A and B). Mice were
imaged before being sacrificed. A significant delay in
tumor growth was observed in the siSNCG-166 group
compared to the NC group after 35 days, based on the
analyses of gross tumor volume and weight and mouse
body weight. A significant decrease in tumor weight was
observed in the NC group compared to the siSNCG-166
group, indicating the importance of SNCG expression
associated with LNCaP tumor growth in vivo. Next,
we examined whether SNCG is involved in tumorigen-
esis of LNCaP cells with subcutaneous injection in
castrated male nude mice. The mice were castrated
after one week and were then injected with stable
RFP-labeled SNCG-overexpressing LNCaP cells or
RFP-expressing LNCaP cells as the control. There was
Figure 4 Functional roles of SNCG in LNCaP-AI cells are ligand-dependent. (A) LNCaP-AI cells were transfected with full-length SNCG cDNA
plasmid or empty vector as the control and selected with puromycin treatment. A stable SNCG-overexpressing clone (RFP-SNCG) and a negative
control clone (RFP) were used for the subsequent experiments. RT-PCR and western blot analysis showed the SNCG expression in RFP-SNCG,
LNCaP-AI and RFP cells. (B) PSA mRNA expression in RFP-SNCG with androgen administration by RT-PCR compared to RFP. (C) RT-PCR was used
to detect the AR mRNA expression in RFP-SNCG with or without DHT administration compared to RFP. (D) Dual-luciferase reporter assays were
performed to show the AR transcriptional activity in LNCaP-AI cells with treatment of androgen. (E) The cellular proliferation was detected by
CCK-8 assay in RFP-SNCG with or without DHT treatment compared to RFP. *P < 0.05, **P < 0.01.
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Figure 5 (See legend on next page.)
Chen et al. BMC Cancer 2012, 12:593 Page 9 of 15
http://www.biomedcentral.com/1471-2407/12/593
(See figure on previous page.)
Figure 5 SNCG promotes tumorigenesis of androgen-dependent prostate cancer cells. (A) Tumorigenesis presented in siSNCG-166 group
(n = 8) and NC group (n = 7, one mouse was sacrificed at 4 weeks after injection due to poor health) after subcutaneous injection of the cells.
(B) Top: Tumor volume was observed twice weekly in the siSNCG-166 group compared to that in the NC group. Bottom: The mean tumor
weight in the siSNCG-166 group was less than that in the NC group. (C): The mean mouse weight was measured twice weekly. No significant
difference was observed between the siSNCG-166-LNCaP group and the NC-LNCaP group. (D) Mice were castrated before the indicated cells
were injected. The tumor-bearing mice showed in RFP-SNCG-LNCaP group (n = 8) and RFP-LNCaP group (n = 8). (E) Top: Tumor volumes were
observed twice weekly in RFP-SNCG-LNCaP group compared to RFP-LNCaP group. Bottom: The mean tumor weight showed in RFP-LNCaP
group and RFP-SNCG-LNCaP group. (F): The mean mouse weight was measured twice weekly. No significant difference was observed between
RFP-SNCG-LNCaP group and RFP-LNCaP group.
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40 days post injection (Figure 5D and E), indicating that
SNCG is involved in mediation of androgen-dependent
prostatic tumorigenesis.
SNCG protein expression is detected in human prostate
cancer samples and correlates with clinicopathologic
features of prostate cancer patients
To investigate the biological roles of SNCG in human
prostate cancer progression and metastasis, an immuno-
histochemistry study was carried out on various tissue
microarrays constructed with primary samples obtained
from prostate cancer patients with known clinical and
pathologic information by radical prostatectomy. SNCG
protein was highly expressed in androgen-dependent
(AD) prostate cancer cells but rarely expressed in benign
tissues (BPH and prostatitis) or androgen-independent
prostate cancer tissues (AIPC) (Figure 6). Statistically,
prostate cancer tissues exhibited significantly higher
SNCG expression than BPH and prostatitis with a P
value of <0.001 (Table 1). To further investigate the cor-
relation between SNCG protein expression and clinico-
pathological features, we evaluated the relationship
between SNCG protein expression and PCa risk factors.
SNCG expression levels were increased significantly in
middle-high-risk PCa with PSA ≥10, Gleason score ≥7
and clinical stage ≥ T2b compared to low-risk PCa.
Moreover, positive SNCG expression was more fre-
quently detected in patients with lymph node metastasis
(P < 0.001). Our data suggest that cytoplasmic expression
of SNCG protein may serve as a prognostic biomarker to
predict the occurrence of metastasis in advanced prostate
cancer. However, there was no significant correlation be-
tween SNCG protein expression and AR state (r = 0.070,
P = 0.881).
Discussion
It has been demonstrated that SNCG is involved in
tumorigenesis and metastasis of a wide range of malig-
nancies [18-23]. SNCG-positive breast cancers have
worse clinical outcome compared with SNCG-negative
breast cancers. Only one report has documented a cor-
relation between SNCG and prostate cancer metastasis[23]. The precise biological functions of SNCG and the
mechanisms of its gene regulation in prostate cancer are
still unknown. Metastasis is one of the hallmarks of
advanced prostate cancer, and contributes to the high
rates of morbidity and mortality in patients. In our studies,
we found that SNCG expression in human prostate cancer
cells results in a more malignant phenotype with increased
cellular proliferation and motility in vitro. SNCG interacts
with AR and enhances PSA expression mediated by
androgen-induced transcriptional activity of AR. We also
demonstrated that SNCG regulates androgen-dependent
tumor size in vivo, and evaluated the clinical value of
detection of SNCG protein expression in diagnosis of
androgen-dependent prostate cancer.
To clarify the functional roles of SNCG in prostate
cancer cells, we knocked down SNCG expression by
siRNA in LNCaP cells and investigated its effects on cel-
lular biological behaviors. Our data showed that silen-
cing of SNCG in LNCaP cells contributes to suppression
of cellular growth and proliferation, induction of cell
cycle arrest at G1 phase and inhibition of cellular migra-
tion and invasion in vitro. These results are consistent
with observations in many other human cancer cells and
indicate that the functions of SNCG are not cell type-
specific. The signaling pathways controlling SNCG gene
regulation are still unknown. Some studies in other can-
cers reported SNCG is implicated in regulation of key
steps of cellular proliferation, invasion and metastasis as
well as survival. It may be activated through several cellu-
lar mechanisms, including reducing BubR1 protein levels
[11,26,27], increasing ER-α transcription [28,29], activat-
ing RHO GTPase [30], MAPK and ElK1 [31], inducing
MMP expression [32], and constitutive activation of
ERK1/2 [19].
It was reported that SNCG expression was strongly
correlated with the stages and Her-2 status [22,33]; how-
ever, this was not associated with ER and PR expression
status in breast cancer studies [34]. We found SNCG ex-
pression is dependent on androgen status in human
prostate cancer cells. Anti-androgen treatment mostly
blocked DHT-induced SNCG expression, indicating that
DHT modulates SNCG expression through AR signaling.
This may account for our observations that SNCG
Figure 6 (See legend on next page.)
Chen et al. BMC Cancer 2012, 12:593 Page 11 of 15
http://www.biomedcentral.com/1471-2407/12/593
(See figure on previous page.)
Figure 6 SNCG protein expression is associated with human prostate cancer progression and metastasis. (A) SNCG protein expression
detected by immunohistochemical (IHC) staining was representative in a series of human prostate tissues on a tissue microarray (TMA). Benign
prostatic hyperplasia tissues and prostatitis showed no SNCG expression in either epithelial or stromal regions. Strong staining of SNCG protein
displayed in androgen-dependent prostate cancers and negative SNCG staining presented in androgen-independent prostate cancers. The left
panel shows H&E staining and the right panel shows SNCG IHC staining (400×). (B) Representative immunohistochemical staining of SNCG (right
line) or AR (light line) protein in local or metastatic human prostate cancer tissues.
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and overexpression of SNCG did not affect tumorigen-
esis in the castrated male mice. To our knowledge, this is
the first report that SNCG expression is dependent on
androgen and plays an important role in prostate cancer
progression. Consequently, SNCG may be closely asso-
ciated with hormone-related tumors, and provide a new
strategy for these tumors.
AR is a ligand-dependent transcription factor and a
member of the class I subgroup of the nuclear receptor
superfamily [35]. The androgen/AR signaling pathway is
demonstrated to play a central role in prostate cancer
development and progression. AR is activated by a ligand-
dependent or a ligand-independent manner [36-38]. Sub-
sequently, the activated receptor homodimerizes with
AREs in the promoters of androgen target genes, result-
ing in activation of downstream gene expression [39].
Previous studies have demonstrated that AR signaling
could be modulated by AR cofactors, such as heat-shock
protein 27 [40], peroxiredoxin 1 [41], Tip60 [42], ARA54
[43], ARA55 [44], peroxisome proliferator-activated re-
ceptor coactivator-1 (PGC-1) [45] and human hetero-
chromatin protein 1isoform HP1β [46]. SNCG has been
shown to interact with ER and enhance ER transcrip-




Prostate cancer tissues (androgen-independent) 5
Prostate cancer tissues (androgen-dependent) 48
PSA <10 22(57.9%)
≥10 26(31.0%)
Gleason score ≤6 19(59.3%)
≥7 29(32.2%)
Clinical stage ≤T2a 13(52.0%)
≥T2b 35(36.1%)
Lymph node invasion Negative 46(42.2%)
positive 2(15.4%)
AR - 19(44.2%)
+ 29(36.7%)involved in mediation of AR signaling, we investigated
the interaction between SNCG and AR proteins in
LNCaP cells. Our results revealed that SNCG interacts
with AR and its interaction is strengthened by DHT
treatment. Although silencing of SNCG had no signifi-
cant effect on AR expression in LNCaP cells, its suppres-
sion influenced PSA expression and AR transcriptional
activity. We suggest that SNCG is a novel co-activator of
AR and may play an important role in the molecular
interaction with AR signaling in prostate cancer cells.
The mechanisms need further exploration, including
how they interact with each other, what downstream fac-
tor they promote or suppress, and so on.
Furthermore, we showed that silencing of SNCG by
siRNA in LNCaP cells reduced tumor growth when the
cells were injected into nude mice. These in vivo studies
were consistent with the previously investigated func-
tions of SNCG in prostate cancer cells in vitro. Our
results indicate that aberrantly high expression of SNCG
is partly responsible for tumor growth and invasion.
Since SNCG expression of prostate cancer cells was
regulated by androgen in vitro, we investigated stable
SNCG-overexpressing LNCaP tumor growth in the
castrated host mice. However, there was no significant





0 0 0 10 <0.001
0 2 0 10 <0.001
0 0 0 5 <0.001
24 31 19 122
9(23.7%) 6(15.8%) 1(3.6%) 38 0.004
15(17.9%) 25(29.8%) 18(21.3%) 84
6(18.8%) 5(15.6%) 2(6.3%) 32 0.037
18(20.0%) 26(28.9%) 17(18.9%) 90
7(28.0%) 3(12.0%) 2(8.0%) 25 0.042
17(17.5%) 28(28.9%) 17(17.5%) 97
24(22.0%) 28(25.7%) 11(10.1%) 109 <0.001
0 3(23.1%) 8(61.5%) 13
8(18.6%) 10(23.3%) 6(13.9%) 43 0.881
16(20.3%) 21(26.6%) 13(16.4%) 79
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androgen-dependent prostate tumorigenesis. When
prostate cancer patients are diagnosed at an advanced
stage of the disease, androgen-deprivation therapy (ADT)
has become the standard therapy. While the contro-
versial topic remains, doctors believe that declining
serum levels of testosterone and aging represent the most
significant risk factors for prostate cancer progression
[47-49]. A previous study claimed that exposure to
reduced androgens may promote prostate tumorigenesis
by activating special molecular events that drive more
aggressive hormone-refractory tumors [50]. However, our
data suggest that ADT therapy regimen in the treatment
of advanced prostate cancer patients might effectively re-
duce some androgen-induced risk factors such as SNCG.
Abate-Shen showed that prostate tumors from low-
testosterone mutant mice shared a similar gene expres-
sion profile to androgen-independent prostate tumors
[50]. They suggested that declining serum levels of tes-
tosterone associated with aging is the main aggressive
factor for prostate cancer. We raised the question
whether it is necessary to perform androgen-deprivation
(ADT) therapy on aged patients if they have high expres-
sion levels of SNCG protein. To address this issue, we
overexpressed SNCG in androgen-independent LNCaP
cells (LNCaP-AI). We found SNCG-overexpressing
LNCaP-AI cells enhanced AR transcriptional activity and
promoted PSA expression and cellular proliferation in re-
sponse to DHT treatment. This suggested that SNCG
may be a malignant risk factor in older men with prostate
cancer.
Our results from a tissue microarray with immuno-
histochemical staining indicated SNCG protein is highly
expressed in androgen-dependent (AD) prostate tumors,
but is rarely expressed in benign tissues. In 122 radical
prostatectomy specimens, 63.9% of SNCG-positive
patients developed peripheral invasion. Only 20% of
SNCG-high-positive (++ or +++) patients have local
cancer. A total of 84.6% of SNCG-high positive (++
or +++) with lymph node metastasis indicate that
SNCG expression is strongly associated with prostate
cancer metastasis. The proportion of SNCG-positive
metastasis is nearly consistent with previous reports
[23]. Although SNCG protein expression was not asso-
ciated with AR status, the high risk in malignant pro-
gression may help us establish efficient treatment strategies
and reduce inappropriate or unnecessary treatments.
SNCG expression was reported in 20% of preneoplastic
lesions in the ovary [12], and was observed in various can-
cer types with lymph node invasion [23]. We found SNCG
was not expressed in benign epithelium cells, but aber-
rantly expressed in advanced malignant states, suggesting
that SNCG may be a tumor-oriented chaperone. The cases
with high SNCG protein expression were found to bestrongly associated with metastatic features. We therefore
suggest SNCG protein expression in biopsy specimens
may assist in distinguishing between potentially aggressive
and potentially non-aggressive disease in prostate cancer
screening. A large number of specimens need to be further
explored to determine if SNCG protein expression is a pre-
dictive biomarker for evaluation of pre-surgery and survival
of prostate cancer patients.
Conclusions
In summary, SNCG is aberrantly expressed in PCa and
is associated with its malignant progression. Our data
provide evidence that SNCG protein expression may
serve as a biomarker for assessment of biopsies to pre-
dict a high risk of prostate cancer progression and me-
tastasis. SNCG is regulated by androgen, interacts with
AR protein and affects AR target gene PSA expression
by enhancing androgen-induced AR transcriptional ac-
tivity, indicating that the functional roles of SNCG in
PCa may be related to the androgen/AR signaling path-
way. Because SNCG is involved in a variety of biological
activities of PCa including cellular proliferation, migra-
tion and invasion in vitro as well as tumorigenesis
in vivo, we suggest that modulation of SNCG expression
might be a useful strategy for developing novel biomed-
ical therapeutics for PCa.
The answers to the reviewers
1. It would be preferable to see an additional AR
dependent cell line e.g. CWR22 or use of the other
siRNAs to see a dose response effect of SNCG
inhibition. We detected the inhibition efficiency of
oligo-166 target to SNCG in CWR22 cells, as
expected, we had observed the inhibition effect of
SNCG with dose dependent of siSNCG-166 in
CWR22 cells. (Additional file 1: Figure S1).
2. The invasion/migration assays demonstrate a modest
inhibition of invasion and migration, considering the
level of SNCG knockdown, what is the mechanism
for this inhibition? Is there an inhibition of MMP
expression or Rho-GTPases for example? We
supplement the experiment of the relation between
inhibition SNCG and MMP using wild type LNCaP
cells and stable cell line of RFP-SNCG-LNCaP and
siSNCG-166-LNCaP (Additional file 2: Figure S2).
From the result we confirmed the expression of
SNCG is involving in the MMP members' regulation.
3. The authors looked at the effects of SNCG inhibition
and increased expression in LnCap cells. Inhibition
of SNCG resulted in decreased proliferation and
accumulation in the G1 phase. Vice versa increased
SNCG caused increased proliferation, however the
authors do not present corresponding information on
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information? Some overexpression experiments were
done later (Additional file 3: Figure S3), here we
primarily show the role of inhibition of SNCG in
LNCaP cells. In this way, it avoids the seeming
confusion of the entire article structure.
4. The authors performed several experiments in
LNCaP-AI cells. They should state how these cells
compare to LNCaP cells in terms of AR levels,
response to androgens, proliferation, etc. AR protein
in LNCaP-AI is higher than LNCaP (Additional file
4: Figure S4). PSA secretion was stimulated with
increasing concentration of DHT in both LNCaP and
LNCaP-AI cells, but the PSA secretion was much
higher for LNCaP cells than for LNCaP-AI cells.
(Additional file 5: Figure S5).
5. The majority of the experiments rely on SNCG
overexpression or knock-down but several of these
experiments lack an important control: the authors
should provide data showing SNCG protein levels for
these experiments. The data should allow the reader
to compare SNCG levels in control and over/
underexpressing cells. This concerns the following
figures: 1C-D, 2A-B, 3C-F and 5A-F. Transient
transfection was used for cytological experiments.
Before the cytological experiment (Figure 1-3), we
repeatedly proved a stable inhibition efficiency of
SNCG by oligo-166 (in fact, more than 3 times). In
Figure 1B, we show one of these experiments with
protein expression. So, we did not show the protein
expression in the every following experiment. The
stably transfected cells screened by puromycin was
used for animal experiments. We will supplement the
fluorescence image of the cells and the protein level
of the stable cell line of SNCG (Additional file 6:
Figure S6). We have confirmed that SNCG protein
expression in LNCaP cells, which were transiently
transfected with SNCG plasmid or siRNA, was
increased or decreased at different intervals up to 7
days (Additional file 7: Figure S7).Additional files
Additional file 1: Figure S1. Western blot analysis was used to
evaluate SNCG protein silence efficiency in CWR22 cells with different
siSNCG-166 concentration.
Additional file 2: Figure S2. Western blot analysis were used to
detected the MMP members expression level with different SNCG
expression state.
Additional file 3: Figure S3. Cell cycles analyzed by flow cytometry.
Up-regulation of SNCG expression in LNCaP promoted cells into S phase
compared to REP-NC.
Additional file 4: Figure S4. RT-PCR (A) and western blot (B) showed
that the AR expression was higher in LNCaP-AI cells than in LNCaP cells
**P<0.01.Additional file 5: Figure S5. Extracted from “Xu B, Sun Y, Tang G, Xu C,
Wang L, Zhang Y, Ji J: Id-l expression in androgen-dependent prostate
cancer is negatively regulated by androgen through androgen receptor.
Cancer letters 2009, 278: 220-9”.
Additional file 6: Figure S6. The stably transfected cell lines were
constructed. The fluorescence image (up) and the protein level (down)
were presented.
Additional file 7: Figure S7. SNCG protein expression at indicated time
points in LNCaP cells that were transfected with SNCG plasmid (A) or
siRNA (B).
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